ClinicalTrials.Veeva

Menu

Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

Kessler Foundation logo

Kessler Foundation

Status and phase

Unknown
Phase 1

Conditions

Stroke
Aphasia

Treatments

Drug: Wait first, then levetiracetam
Drug: Levetiracetam first, then wait

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00227461
AMBarrett1
none applicable

Details and patient eligibility

About

The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.

Full description

In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Stroke
  • Aphasia
  • Can give consent

Exclusion criteria

  • Renal failure
  • Pregnancy
  • Other neurological condition

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

50 participants in 2 patient groups

Wait control
Other group
Description:
Levitiracetam is started after a delay, with dosage and administration as described below.
Treatment:
Drug: Levetiracetam first, then wait
Treatment first
Experimental group
Description:
Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.
Treatment:
Drug: Wait first, then levetiracetam

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems